Global Pharmacogenetic Testing Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 11,442.40 |
 CAGR |
% |
| Major Markets Players |
>全球药物基因组学测试市场，按类型（全基因组测序、全外显子组测序、基于阵列的测试和单基因测试）、基因类型（CYP2C19、CYP2D6、CYP2C9 和 VKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DX 和 MAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT 等）、药物类型（处方药、保健食品、娱乐性药物、草药补充剂、维生素和非处方药）、样本（血液和唾液）、治疗领域（心脏病学、胃肠病学、麻醉学、基因组学、内分泌学、免疫学和超敏反应，皮肤病学、妇科、肿瘤学、神经病学等）、应用（临床实践、药物开发和药物监管）、最终用户（医疗保健提供商、制药和生物技术公司、研究中心和学术机构等）、分销渠道（医院药房、零售药房、邮购药房和直接面向客户服务）——行业趋势和预测到 2030 年。
药物基因组学测试市场分析和规模
预计全球药物基因组学检测市场将在 2023 年至 2030 年的预测期内实现市场增长。个性化医疗的日益普及推动了市场的发展，而个性化医疗是一个需要药物基因组学检测市场的市场。
整合电子健康记录 (EHR) 是市场增长的重要驱动力。慢性病和复杂疾病的增加预计将为市场增长创造机会。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，市场将以 8.7% 的复合年增长率增长，预计到 2030 年将达到 114.424 亿美元。基因组技术的进步预计将推动市场的扩张。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史性的一年 |
2021（可定制 2015-2020） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
类型（全基因组测序、全外显子组测序、基于阵列的测试和单基因测试）、基因类型（CYP2C19、CYP2D6、CYP2C9 和 VKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DX 和 MAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT 等）、药物类型（处方药、保健食品、娱乐性药物、草药补充剂、维生素和非处方药）、样本（血液和唾液）、治疗领域（心脏病学、胃肠病学、麻醉学、基因组学、内分泌学、免疫学和超敏反应、皮肤病学、妇科肿瘤学、神经病学等）、应用（临床实践、药物开发和药物监管）、最终用户（医疗保健提供商、制药和生物技术公司、研究中心和学术机构等）、分销渠道（医院药房、零售药房、邮购药房和直接面向客户服务） |
|
覆盖国家 |
美国、加拿大、墨西哥、法国、德国、西班牙、意大利、英国、西班牙、荷兰、俄罗斯、土耳其、瑞士、欧洲其他地区、中国、日本、泰国、印度、韩国、澳大利亚、新加坡、印度尼西亚、菲律宾、马来西亚、亚太其他地区、巴西、阿根廷、南美洲其他地区、阿联酋、沙特阿拉伯、南非、以色列、埃及、中东和非洲其他地区 |
|
涵盖的市场参与者 |
PerkinElmer Inc.、Illumina, Inc.、Thermo Fisher Scientific Inc.、Dynamic DNA Laboratories、Sonic Healthcare、QIAGEN、Eurofins Scientific、23andMe, Inc、OneOme、BGI、PacBio、MD Labs、GENEWIZ、PGXT、Luminex Corporation 和 Myriad Genetics, Inc. 等 |
药物基因组学测试市场定义
药物基因组学检测包括检查个人基因图谱的服务，以确定个人基因如何影响对特定药物的反应。这种专门的基因检测可识别可能影响不同药物代谢、疗效和潜在副作用的特定基因变异。医疗保健专业人员可以为患者定制药物选择和剂量，以改善治疗效果、减少副作用并提高整体药物疗效。这是通过了解患者的遗传倾向来实现的。这种个性化的药物选择和剂量方法可能会改善医疗保健质量和患者治疗效果。
药物基因组学测试市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 个性化医疗的普及
药物基因组学检测在个性化医疗中发挥着至关重要的作用，它可以根据个人的基因组成定制药物治疗方案。这种创新方法涉及分析个人的基因变异，这可能会影响他们代谢和对特定药物的反应。这些基因差异会影响药物的有效性和潜在的副作用，使药物基因组学检测成为个性化治疗计划的宝贵工具。
通过检查一个人独特的基因图谱，医疗保健提供者可以识别决定其身体如何处理和利用药物的基因标记。这些信息允许定制药物选择和剂量以优化治疗结果。例如，有些人可能具有基因变异，使他们对某些药物更敏感，需要较低的剂量才能达到预期的治疗效果而不会产生不良反应。另一方面，一些基因变异可能需要更高的剂量才能达到相同的效果。这种量身定制的方法最大限度地减少了通常与药物选择相关的“反复试验”，降低了不良反应的风险并提高了治疗效果。它使医疗保健专业人员能够做出明智的决定，并根据患者的遗传倾向开出更可能对患者有效的药物。最终，药物基因组学测试极大地促进了个性化医疗的范式，通过促进更精确和个性化的治疗策略来彻底改变医疗保健，以获得更好的患者结果。
因此，市场受益于这种需求激增，见证了研发活动的持续增长，以创造更全面、更准确的检测解决方案。下一代测序 (NGS)和其他分子诊断技术等技术进步进一步提高了这些测试的准确性和可负担性。个性化医疗的兴起与蓬勃发展的市场之间形成了相互促进的关系，两者都对医疗保健领域产生了重大影响，并有望在未来实现个性化、有效和以患者为中心的治疗，这有望推动市场增长。
- 基因组技术的进步
基因组创新的不断涌现大大提高了基因检测的精度、速度和成本效益。新一代测序 (NGS) 和其他尖端分子诊断技术已成为关键工具，彻底改变了遗传信息的分析和解释方式。这些先进基因组技术的整合提高了药物基因组学检测的准确性和范围，可以全面评估个人的基因图谱。这反过来又使医疗保健专业人员能够根据患者独特的基因构成做出明智的药物选择、剂量和治疗策略决策。
此外，CRISPR-Cas9 基因编辑技术在研究特定基因变异的功能影响方面显示出良好的前景。该技术使研究人员能够精确修改基因，模仿某些基因变异并阐明其对药物代谢和反应的影响。这些进步共同促进了市场的完善和扩张，使未来更接近根据每个人独特的基因蓝图量身定制药物，这有望推动市场增长。
机会
- 与电子健康记录 (EHR) 集成
无缝集成可实现高效、集中的遗传数据存储以及全面的患者健康记录。这种融合提高了医疗专业人员对药物遗传学信息的可访问性和可用性，使他们能够做出实时数据驱动的决策。医生可以在治疗计划期间轻松获取遗传学见解，确保开出的药物符合患者独特的基因构成。通过这种集成实现的效率提升加速了药物遗传学测试的采用，有助于改善患者护理、简化工作流程，并最终促进市场增长。
此外，与 EHR 的整合有助于更广泛地开展研究和数据分析。EHR 中汇总和去识别的基因数据可用于研究和临床研究，推动药物基因组学的发展。制药公司、研究机构和医疗保健提供商可以利用这些数据来加强药物开发、验证遗传关联并优化治疗策略。市场与 EHR 之间的这种合作推动了创新。它培育了一个协同生态系统，使医疗保健行业受益，并通过加强研究、产品开发和数据驱动的决策推动市场向前发展，预计将为市场增长创造机会。
克制/挑战
- 依赖医学和基因组学专家来解释结果
市场面临一个显著的限制，即严重依赖医学和基因组学专家来解释结果。基因数据的复杂性需要专业知识和专长才能准确而有意义地理解。药物基因组学测试结果的正确解释在很大程度上取决于高技能的专业人员，包括遗传学家、药理学家和基因组学专家。这种依赖性对药物基因组学测试的可扩展性和广泛采用构成了挑战。合格专家数量有限，精确解释所需的时间和精力往往会延迟向医疗保健从业者和患者提供可操作的见解。此外，这种对专家的依赖会导致成本和资源利用率增加，阻碍药物基因组学测试与常规临床实践的无缝集成。要克服这一限制，需要在自动化数据分析工具、用户友好界面和综合教育计划方面取得进步，以使更广泛的医疗保健专业人员能够准确解释和利用药物基因组学测试结果。因此，市场在根据个人的基因构成为其量身定制药物疗法方面前景广阔。一个关键挑战在于对医学和基因组学专家的依赖，以解释测试结果。基因数据的复杂性需要特定的专业知识，这使得解释结果和做出临床决策具有挑战性，预计这会抑制市场增长。
近期发展
- 2023 年 5 月，PerkinElmer Inc. 宣布成立 Revvity, Inc.，作为一家基于科学的解决方案提供商，利用诊断和生命科学领域的进步来改善全球人民的生活。此前，该业务与 PerkinElmer, Inc. 有关联。Revvity 的客户来自各个行业，包括制药和生物技术、诊断实验室、学术界和政府组织。Revvity 提供试剂、耗材、检测试剂、仪器和软件
- 2022 年 10 月，PacBio 和 Twist Bioscience Corporation 宣布推出首批现成的长读基因组组合。这些固定的 Twist Alliance 基因组组合旨在高效且经济地捕获目标区域。此外，客户将能够使用 PacBio HiFi 读长创建完全适应且可扩展的基因组设计，用于测序
全球药物基因组学测试市场范围
全球药物基因组学测试市场根据类型、基因类型、药物类型、样本、治疗领域、应用、最终用户和分销渠道细分为八个值得注意的细分市场。这些细分市场之间的增长将帮助您分析行业中的主要增长细分市场，并为用户提供有价值的市场概览和市场洞察，以做出战略决策，确定核心市场应用
类型
- 全基因组测序
- 全外显子组测序
- 基于数组的测试
- 单基因测试
根据类型，市场分为全基因组测序、全外显子组测序、基于阵列的测试和单基因测试。
基因类型
- CYP2C19
- CYP2D6
- CYP2C9 和 VKORC1
- CYP1A2
- HLA-B*1502
- HLA-B*5701
- 细胞色素P450
- OPRM1
- ONCOTYPE DX® 和 MAMMAPRINT®
- DRD3
- D4D4
- SLC6A4
- 高温气冷堆2A/C
- 三甲胺磷
- 其他的
根据基因类型，市场细分为 CYP2C19、CYP2D6、CYP2C9 和 VKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DX 和 MAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT 等。
药物类型
根据药品类型，市场分为处方药、营养药品、娱乐性药物、草药补充剂、维生素和非处方药。
样本
- 血
- 唾液
根据样本，市场分为血液和唾液。
治疗领域
- 心脏病学
- 胃肠病学
- 麻醉学
- 基因组学
- 内分泌学
- 免疫学和超敏反应
- 皮肤科
- 妇科
- 肿瘤学
- 神经病学
- 其他的
根据治疗领域，市场细分为心脏病学、胃肠病学、麻醉学、基因组学、内分泌学、免疫学和超敏反应、皮肤病学、妇科学、肿瘤学、神经病学等。
应用
- 临床实践
- 药物开发
- 药品监管
根据应用，市场分为临床实践、药物开发和药物监管。
最终用户
- 医疗保健提供者
- 制药及生物技术公司
- 中心和学术机构
- 其他的
根据最终用户，市场分为医疗保健提供商、制药和生物技术公司、研究中心和学术机构等。
分销渠道
- 医院药房
- 零售药店
- 邮购药店
- 直接面向客户的服务
根据分销渠道，市场分为医院药房、零售药房、邮购药房和直接面向客户的服务。
区域分析/见解：药物基因组学检测市场
对全球药物基因组学测试市场进行分析，并根据上述类型、基因类型、药物类型、样本、治疗领域、应用、最终用户和分销渠道提供市场规模洞察和趋势。
市场报告涉及的国家包括美国、加拿大、墨西哥、法国、德国、西班牙、意大利、英国、西班牙、荷兰、俄罗斯、土耳其、瑞士、欧洲其他地区、中国、日本、泰国、印度、韩国、澳大利亚、新加坡、印度尼西亚、菲律宾、马来西亚、亚太其他地区、巴西、阿根廷、南美洲其他地区、阿联酋、沙特阿拉伯、南非、以色列、埃及以及中东和非洲其他地区。
美国有望凭借其先进的基础设施和广泛的高质量医疗基础设施中心网络在北美地区占据主导地位。德国有望凭借其在生物技术和医疗保健方面的研发不断增加而在欧洲地区占据主导地位。日本有望凭借其对药物基因组学测试市场的需求不断增加和认识不断提高而占据亚太地区主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
药物基因组学测试市场竞争格局及份额分析
全球药物基因组学测试市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、区域业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
全球药物基因组学检测市场的一些主要参与者包括 PerkinElmer Inc.、Illumina, Inc.、Thermo Fisher Scientific Inc.、Dynamic DNA Laboratories、Sonic Healthcare、QIAGEN、Eurofins Scientific、23andMe, Inc、OneOme、BGI、PacBio、MD Labs、GENEWIZ、PGXT、Luminex Corporation 和 Myriad Genetics, Inc. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’SFIVE FORCES
4.3 INDUSTRY INSIGHTS AND STRATEGIC ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING ADOPTION OF PERSONALIZED MEDICINE
5.1.2 ADVANCEMENTS IN GENOMIC TECHNOLOGIES
5.1.3 INCREASING CHRONIC AND COMPLEX DISEASES
5.1.4 ROLE OF PHARMACOGENETIC TESTING IN DRUG DISCOVERY AND DEVELOPMENT
5.2 RESTRAINTS
5.2.1 DEPENDENCY ON THE MEDICAL AND GENOMIC EXPERT FOR RESULT INTERPRETATION
5.2.2 ETHICAL AND PRIVACY CONCERNS ASSOCIATED WITH PHARMACOGENETIC TESTING
5.3 OPPORTUNITIES
5.3.1 INTEGRATION WITH ELECTRONIC HEALTH RECORDS (EHRS)
5.3.2 ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING INTEGRATION IN HEALTHCARE
5.4 CHALLENGES
5.4.1 CHALLENGES IN CLINICAL IMPLEMENTATION OF PHARMACOGENETICS
5.4.2 COMPLEXITY ASSOCIATED WITH PHARMACOGENETIC TESTING RESULTS
6 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE
6.1 OVERVIEW
6.2 WHOLE GENOME SEQUENCING
6.2.1 NEXT GENERATION SEQUENCING (NGS)
6.2.2 SANGER SEQUENCING
6.3 WHOLE EXOME SEQUENCING
6.3.1 NEXT GENERATION SEQUENCING (NGS)
6.3.2 SANGER SEQUENCING
6.4 ARRAY-BASED TESTS
6.4.1 GLASS SLIDE ARRAYS
6.4.2 IN—SITU SYNTHESIZED ARRAYS
6.4.3 SELF ASSEMBLED ARRAYS
6.5 SINGLE GENE TESTS
6.5.1 NEXT GENERATION SEQUENCING (NGS)
6.5.2 SANGER SEQUENCING
7 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE
7.1 OVERVIEW
7.2 CYP2C19
7.3 CYP2D6
7.4 CYP2C9 AND VKORC1
7.5 CYP1A2
7.6 HLA-B*1502
7.7 HLA-B*5701
7.8 CYP2D
7.9 OPRM1
7.1 ONCOTYPE DX* AND MAMMAPRINT
7.11 DRD3
7.12 D4D4
7.13 SLC6A4
7.14 HTR2A/C
7.15 TMPT
7.16 OTHERS
8 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE
8.1 OVERVIEW
8.2 PRESCRIPTION DRUGS
8.3 NUTRACEUTICALS
8.4 RECREATIONAL DRUGS
8.5 HERBAL SUPPLEMENTS
8.6 VITAMINS
8.7 OVER-THE-COUNTER MEDICATIONS
9 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE
9.1 OVERVIEW
9.2 BLOOD
9.3 SALIVA
10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA
10.1 OVERVIEW
10.2 CARDIOLOGY
10.3 GASTROENTEROLOGY
10.4 ANESTHESIOLOGY
10.5 GENOMICS
10.6 ENDOCRINOLOGY
10.7 IMMUNOLOGY & HYPERSENSITIVITY
10.8 DERMATOLOGY
10.9 GYNECOLOGY
10.1 ONCOLOGY
10.11 NEUROLOGY
10.12 OTHERS
11 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 CLINICAL PRACTICE
11.2.1 SIDE EFFECTS
11.2.2 DRUG EFFECTIVENESS
11.2.3 DOSAGE
11.3 DRUG DEVELOPMENT
11.3.1 DRUG EFFECTIVENESS
11.3.2 DOSAGE
11.3.3 SIDE EFFECTS
11.4 DRUG REGULATION
11.4.1 SIDE EFFECTS
11.4.2 DRUG EFFECTIVENESS
11.4.3 DOSAGE
12 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE PROVIDERS
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.4 RESEARCH CENTRES AND ACADEMIC INSTITUTES
12.5 OTHERS
13 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITAL PHARMACY
13.3 RETAIL PHARMACIES
13.4 MAIL-ORDER PHARMACIES
13.5 DIRECT-TO-CUSTOMER SERVICES
14 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.3 EUROPE
14.4 ASIA-PACIFIC
14.5 SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
15 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 QIAGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SONIC HEALTHCARE
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BGI
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 23ANDME, INC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 DYNAMIC DNA LABORATORIES
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 EUROFINS SCIENTIFIC (2022)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 GENEWIX (A SUBSIDIARY OF AZENTA LIFE SCIENCE)
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 LUMINEX CORPORATION (A SUBSIDIARY OF DIASORIN)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 MD LABS
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 MYRIAD GENETICS, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 ONEOME
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 PACBIO
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PERKINELMER INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 PGXT
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL CYP1A2 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL HLA-B*1502 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL HLA-B*5701 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL CYP2D IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL OPRM1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL ONCOTYPE DX* AND MAMMAPRINT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL DRD3 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL D4D4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL TMPT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL NUTRACEUTICALS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL HERBAL SUPPLEMENTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL VITAMINS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL BLOOD IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL SALIVA IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERPAEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL CARDIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL GASTROENTEROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL ANESTHESIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL GENOMICS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL ENDOCRINOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 GLOBAL IMMUNOLOGY & HYPERSENSITIVITY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL DERMATOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 GLOBAL GYNECOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL ONCOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL NEUROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 53 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 55 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 61 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 U.S. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 U.S. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 U.S. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 86 U.S. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 87 U.S. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 U.S. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 90 U.S. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 91 U.S. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 U.S. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 93 U.S. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 94 U.S. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 95 U.S. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 U.S. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CANADA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 CANADA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 103 CANADA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 105 CANADA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 106 CANADA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 CANADA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 CANADA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 CANADA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 CANADA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 CANADA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 MEXICO PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 113 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 114 MEXICO WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 115 MEXICO ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 121 MEXICO PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 MEXICO CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 123 MEXICO DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 MEXICO DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 MEXICO PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 MEXICO PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 EUROPE PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 128 EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 129 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 EUROPE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 EUROPE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 EUROPE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 134 EUROPE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 EUROPE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 136 EUROPE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 137 EUROPE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 EUROPE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 EUROPE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 EUROPE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 143 GERMANY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 GERMANY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 146 GERMANY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 147 GERMANY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 GERMANY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 149 GERMANY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 GERMANY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 151 GERMANY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 152 GERMANY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 GERMANY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 154 GERMANY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 155 GERMANY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 GERMANY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 157 GERMANY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 158 FRANCE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 159 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 160 FRANCE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 162 FRANCE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 163 FRANCE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 164 FRANCE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 165 FRANCE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 166 FRANCE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 167 FRANCE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 168 FRANCE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 FRANCE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 170 FRANCE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 FRANCE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 172 FRANCE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 173 U.K. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 U.K. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 U.K. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 U.K. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 178 U.K. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 181 U.K. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 182 U.K. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 183 U.K. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 184 U.K. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 185 U.K. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 U.K. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 187 U.K. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 188 ITALY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 194 ITALY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 196 ITALY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 197 ITALY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 198 ITALY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 199 ITALY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 200 ITALY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 201 ITALY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 ITALY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 SPAIN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 SPAIN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 206 SPAIN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 SPAIN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 SPAIN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 209 SPAIN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 SPAIN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 211 SPAIN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 212 SPAIN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 SPAIN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 SPAIN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 SPAIN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 SPAIN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 SPAIN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 221 RUSSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 222 RUSSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 224 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 RUSSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 228 RUSSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 229 RUSSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 RUSSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 232 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 233 TURKEY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 234 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 235 TURKEY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 236 TURKEY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 237 TURKEY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 238 TURKEY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 239 TURKEY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 TURKEY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 241 TURKEY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 242 TURKEY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 243 TURKEY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 244 TURKEY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 245 TURKEY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 246 TURKEY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 247 TURKEY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 264 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 265 NETHERLANDS WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 266 NETHERLANDS ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 267 NETHERLANDS SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 278 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 279 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 SWITZERLAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 281 SWITZERLAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 282 SWITZERLAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 284 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 286 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 287 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 SWITZERLAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SWITZERLAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 SWITZERLAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 291 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 295 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 297 ASIA-PACIFIC WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 299 ASIA-PACIFIC SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 300 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 301 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 302 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 303 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 304 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 305 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 306 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 307 ASIA-PACIFIC DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 308 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 JAPAN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 311 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 312 JAPAN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 313 JAPAN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 314 JAPAN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 315 JAPAN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 316 JAPAN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 JAPAN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 318 JAPAN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 319 JAPAN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 320 JAPAN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 321 JAPAN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 322 JAPAN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 JAPAN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 324 JAPAN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 325 CHINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 328 CHINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 329 CHINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 CHINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 331 CHINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 CHINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 333 CHINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 334 CHINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 335 CHINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 CHINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 CHINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 CHINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 339 CHINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 340 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 341 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 342 SOUTH KOREA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 SOUTH KOREA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 SOUTH KOREA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 346 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 347 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 348 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 349 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 SOUTH KOREA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 SOUTH KOREA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 352 SOUTH KOREA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 354 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 355 INDIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 356 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 357 INDIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 INDIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 359 INDIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 360 INDIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 361 INDIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 INDIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 363 INDIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 364 INDIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 INDIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 366 INDIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 367 INDIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 INDIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 369 INDIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 370 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 371 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 372 AUSTRALIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 AUSTRALIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 374 AUSTRALIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 375 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 376 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 378 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 379 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 380 AUSTRALIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 381 AUSTRALIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 AUSTRALIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 383 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 384 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 385 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 386 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 387 SINGAPORE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 388 SINGAPORE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 389 SINGAPORE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 390 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 391 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 392 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 393 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 394 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 395 SINGAPORE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 396 SINGAPORE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 397 SINGAPORE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 398 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 399 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 400 THAILAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 THAILAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 403 THAILAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 THAILAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 THAILAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 406 THAILAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 407 THAILAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 408 THAILAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 409 THAILAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 410 THAILAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 THAILAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 THAILAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 THAILAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 414 THAILAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 415 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 416 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 417 MALAYSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 418 MALAYSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 419 MALAYSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 420 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 421 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 422 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 423 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 424 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 425 MALAYSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 426 MALAYSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 427 MALAYSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 428 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 429 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 430 INDONESIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 431 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 432 INDONESIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 433 INDONESIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 434 INDONESIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 435 INDONESIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 436 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 437 INDONESIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 438 INDONESIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 439 INDONESIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 440 INDONESIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 441 INDONESIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 442 INDONESIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 443 INDONESIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 444 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 445 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 446 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 447 PHILIPPINES WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 448 PHILIPPINES ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 449 PHILIPPINES SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 450 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 451 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 452 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 453 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 454 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 455 PHILIPPINES CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 456 PHILIPPINES DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 457 PHILIPPINES DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 458 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 459 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 460 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 461 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 462 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 463 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 SOUTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 465 SOUTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 466 SOUTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 467 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 468 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 469 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 470 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 471 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 472 SOUTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 473 SOUTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 474 SOUTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 476 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 477 BRAZIL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 478 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 479 BRAZIL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 480 BRAZIL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 481 BRAZIL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 482 BRAZIL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 483 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 484 BRAZIL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 485 BRAZIL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 486 BRAZIL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 487 BRAZIL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 488 BRAZIL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 489 BRAZIL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 490 BRAZIL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 491 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 492 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 493 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 494 ARGENTINA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 495 ARGENTINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 496 ARGENTINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 497 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 498 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 499 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 500 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 501 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 502 ARGENTINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 503 ARGENTINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 504 ARGENTINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 505 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 506 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 507 REST OF SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 508 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 509 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 510 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 511 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 512 MIDDLE EAST AND AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 513 MIDDLE EAST AND AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 514 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 515 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 516 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 517 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 518 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 519 MIDDLE EAST AND AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 520 MIDDLE EAST AND AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 521 MIDDLE EAST AND AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 522 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 523 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 524 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 525 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 526 SOUTH AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 527 SOUTH AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 528 SOUTH AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 529 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 530 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 532 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 533 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 534 SOUTH AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 535 SOUTH AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 536 SOUTH AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 537 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 538 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 539 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 540 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 541 SAUDI ARABIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 542 SAUDI ARABIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 543 SAUDI ARABIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 544 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 545 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 546 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 547 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 548 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 549 SAUDI ARABIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 550 SAUDI ARABIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 551 SAUDI ARABIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 552 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 553 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 554 U.A.E. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 555 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 556 U.A.E. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 557 U.A.E. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 558 U.A.E. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 559 U.A.E. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 560 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 561 U.A.E. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 562 U.A.E. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 563 U.A.E. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 564 U.A.E. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 565 U.A.E. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 566 U.A.E. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 567 U.A.E. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 568 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 569 ISRAEL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 570 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 571 ISRAEL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 572 ISRAEL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 573 ISRAEL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 574 ISRAEL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 575 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 576 ISRAEL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 577 ISRAEL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 578 ISRAEL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 579 ISRAEL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 580 ISRAEL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 581 ISRAEL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 582 ISRAEL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 583 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 584 EGYPT PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 585 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 586 EGYPT WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 587 EGYPT ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 588 EGYPT SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 589 EGYPT PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 590 EGYPT PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 591 EGYPT PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 592 EGYPT PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 593 EGYPT PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 594 EGYPT CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 595 EGYPT DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 596 EGYPT DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 597 EGYPT PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 598 EGYPT PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 599 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 GLOBAL PHARMACOGENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PHARMACOGENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PHARMACOGENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PHARMACOGENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PHARMACOGENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL PHARMACOGENETIC TESTING MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 10 INCREASING ADOPTION OF PERSONALIZED MEDICINE IS DRIVING THE GROWTH OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING MARKET
FIGURE 13 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2022
FIGURE 14 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2022
FIGURE 18 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2023-2030 (USD MILLION)
FIGURE 19 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, CAGR (2023-2030)
FIGURE 20 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2022
FIGURE 22 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 23 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 24 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2022
FIGURE 26 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2023-2030 (USD MILLION)
FIGURE 27 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, CAGR (2023-2030)
FIGURE 28 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, LIFELINE CURVE
FIGURE 29 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2022
FIGURE 30 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
FIGURE 31 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, CAGR (2023-2030)
FIGURE 32 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, LIFELINE CURVE
FIGURE 33 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2022
FIGURE 34 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2022
FIGURE 38 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 39 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 40 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 42 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 43 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 44 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 GLOBAL PHARMACOGENETIC TESTING MARKET: SNAPSHOT (2022)
FIGURE 46 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 47 NORTH AMERICA PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 48 EUROPE PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 49 AISA-PACIFIC PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
